Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Mizuho sees Rivian (RIVN) as best-positioned EV in near term; Cantor starts at Overweight
-
Cantor Fitzgerald Starts Rivian Automotive Inc (RIVN) at Overweight, sees good entry point
-
Merck (MRK) PT Raised to $135 at Cantor Fitzgerald on Increased Confidence In Sales Growth Post 2028E
-
VERU ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Veru Inc. and Encourages Investors to Contact the Firm
-
Form 424B3 Cantor Fitzgerald Income
-
Lanvin Group (LANV) Debuts on NYSE under Ticker "LANV"
-
Lanvin Group Debuts on NYSE under Ticker "LANV"
-
Satellogic Inc (SATL) Provides Business Update
-
Satellogic Provides Business Update
-
Prothena (PRTA) Prices 3.25M Share Offering at $56.50/sh
-
Prothena Announces Pricing of Public Offering of 3,250,000 Ordinary Shares
-
Orchid Island Capital Announces December 2022 Monthly Dividend and November 30, 2022 RMBS Portfolio Characteristics
-
Prothena Corp. (PRTA) Announces 3M Share Proposed Public Offering of Ordinary Shares
-
Prothena Announces Proposed Public Offering of Ordinary Shares
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Generac, Veru, and F45 Training and Encourages Investors to Contact the Firm
-
ADMA Biologics Announces Closing of $69 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
ADMA Biologics Announces Closing of $69 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Form N-CSRS CANTOR FITZGERALD SUSTAI For: Sep 30
-
Cantor Fitzgerald Starts CleanSpark Inc. (CLSK) at Overweight
-
Third Quarter 2022: Increase in Reservations and Multiple International Partnerships Signed
-
Third Quarter 2022: Increase in Reservations and Multiple International Partnerships Signed
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Generac, and Veru and Encourages Investors to Contact the Firm
-
ADMA Biologics (ADMA) Prices Public Offering for $60 Million of Common Stock
-
ADMA Biologics Announces Pricing of Public Offering for $60 Million of Common Stock
-
ADMA Biologics Announces Pricing of Public Offering for $60 Million of Common Stock
-
X4 Pharmaceuticals (XFOR) Prices $65.0 Million Public Offering of Common Stock, Warrants
-
X4 Pharmaceuticals Prices $65.0 Million Public Offering
-
Cantor Fitzgerald Calls Udemy Inc (UDMY) New Top Pick
-
X4 Pharmaceuticals (XFOR) to Offer Common Stock
-
X4 Pharmaceuticals Announces Proposed Public Offering
-
ADMA Biologics Announces Proposed Public Offering of Common Stock
-
ADMA Biologics Announces Proposed Public Offering of Common Stock
-
Form SC 13G Jaguar Global Growth Filed by: CANTOR FITZGERALD SECURITIES
-
Form SC 13G Cartica Acquisition Corp Filed by: CANTOR FITZGERALD SECURITIES
-
Form SC 13G Infinite Acquisition Filed by: CANTOR FITZGERALD SECURITIES
-
Form SC 13G Target Global Acquisitio Filed by: CANTOR FITZGERALD SECURITIES
-
Cantor Fitzgerald remains bullish after touring Lucid's (LCID) Arizona facility
-
Veru, Inc. (VERU) PT Lowered to $22 at Cantor Fitzgerald
-
Organogenesis Holdings Inc. to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech Conference
-
Jeune Aesthetics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference
-
Form 8-K Cantor Fitzgerald Income For: Nov 30
-
VYNE Therapeutics to Participate in Cantor Fitzgerald’s Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference
-
Edesa Biotech to Participate in the 2022 Cantor Fitzgerald Dermatology Conference
-
NeuroSense Announces Third Quarter 2022 Financial Results and Provides Business Update
-
Aziyo Biologics (AZYO) Announces Pricing of $11.2 Million Public Offering of Common Stock
-
Aziyo Biologics, Inc. Announces Pricing of $11.2 Million Public Offering of Common Stock
-
Novan to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference
-
Novan to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference
-
Outlook Therapeutics® to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference
-
Akari Therapeutics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference

